(RTTNews) – Today’s Daily Dose brings you news about Abeaona’s leadership and Board transitions, GENFIT’s deal with LabCorp., FDA hold on Inovio’s planned Phase 2/3 Covid-19 vaccine trial, the new CEO of Merck KGaA, and label expansion of Pfizer’s blockbuster drug Xeljanz.
1. Abeona Plunges as CEO, Directors Resign
Abeona Therapeutics Inc. (ABEO) announced that João Siffert resigned from his positions as CEO, Head of Research and Development, and Chief Medical Officer, as well as member of the Board of Directors, on September 23, 2020.
The company added that on September 27, 2020, Brian Pereira, Stefano Buono, Stephen Howell, George Migausky and Shawn Tomasello had all stepped down from the Board, effective immediately.
Abeona is reviewing and exploring all strategic options and alternatives to maximize stakeholder value, including its sale.
ABEO touched a new 52-week low of $1.07 in intraday trading Monday, before closing at $1.09, down 41.40%.